^
    Apply
    XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma (NCT02721459)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    09/07/2016
    Primary completion :
    10/31/2019
    Completion :
    03/01/2025
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Zelboraf (vemurafenib) • Cotellic (cobimetinib) • XL888
    Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma (NCT01657591)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Completed
    Last update posted :
    01/19/2023
    Initiation :
    07/27/2012
    Primary completion :
    09/20/2016
    Completion :
    09/21/2021
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Zelboraf (vemurafenib) • XL888